Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Mineralys Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Research and development
26.3
70.4
169
132
General and administrative
5.23
14.3
23.8
38.6
Operating expenses
31.5
84.7
192
171
Operating income
-31.5
-84.7
-192
-171
Other non-operating income
1.68
12.8
14.6
16
Income tax
0
Net income
-29.8
-71.9
-178
-155
EBITDA
-84.7
-192
-171
EPS, basic
-5.77
-1.99
-3.66
-2.29
EPS, diluted
-5.77
-1.99
-3.66
-2.29
Shares, basic (weighted)
5.17
36.2
48.5
67.7
Shares, diluted (weighted)
5.17
36.2
48.5
67.7
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
87.7
49.3
114
173
Other current assets
2.7
12.5
7.16
4.75
Total current assets
113
249
205
661
Property, plant and equipment
0
0.05
0.04
Long-term investments
2.48
0
Other non-current assets
1.63
0.05
0.5
0.38
Total assets
114
252
206
662
Accounts payable
1.91
0.6
0.48
2.02
Accrued liabilities
6.16
9.88
14.2
13.1
Total current liabilities
8.07
10.5
14.6
15.1
Total liabilities
167
10.5
14.6
15.1
Paid-in capital
0.54
366
494
1,104
Retained earnings
-52.8
-125
-303
-457
Shareholders' equity
-52.3
241
191
647
Total equity
-52.3
241
191
647
Total liabilities and equity
114
252
206
662
Shares outstanding
6.42
41.1
49.8
81.5
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-29.8
-71.9
-178
-155
Depreciation and amortization
0
0.04
0.06
Stock-based compensation
0.46
5.06
11.3
19.3
Deferred income tax
0
0
0
0
Change in payables
3.01
2.42
4.16
0.43
Cash from operations
-29.2
-81.2
-166
-142
Capital expenditures
0
-0.1
-0.02
Cash from investing
-21.8
-160
115
-390
Stock issued
0
0.19
0.3
12.8
Cash from financing
128
203
116
591
Net change in cash
77
-38.4
64.8
58.8
Free cash flow
-81.2
-166
-142
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $25.86 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-63.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-52.3%
Net income / average total assets.
Return on invested capital (ROIC)
-71.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
238.1%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
221.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
79.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
39.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
135.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
34.5x
Current assets / current liabilities.
Quick ratio
7.16x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.16x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.00x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.0%
Total debt / total assets.
Liabilities / assets
17.5%
Total liabilities / total assets.
Net debt
-$138.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.64
Cash from operations / diluted weighted shares.
Book value per share
$6.24
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
4.15x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.15x
Market cap / tangible book value, when positive.
Earnings yield
-15.3%
Net income / market cap (the inverse of P/E).
Was Mineralys Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $154.7M.
How much free cash flow did Mineralys Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $142.4M minus capital expenditures of $15.0K left free cash flow of -$142.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.